Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1927881 | 1.00 | LDHA (0.53) | LDHAACENPC1RAB9APPARG | |
| SCHEMBL1760820 | 1.00 | LDHA (0.53) | LDHAACENPC1RAB9APPARG | |
| SCHEMBL1177136 | 0.86 | PDCD1 (0.56) | LDHANPC1RAB9APPARGFFAR1 | |
| SCHEMBL1177223 | 0.86 | PDCD1 (0.56) | LDHANPC1RAB9APPARGFFAR1 | |
| SCHEMBL1097490 | 0.86 | LDHA (0.63) | LDHANPC1RAB9APPARGFFAR1 | |
| SCHEMBL1177224 | 0.86 | PDCD1 (0.56) | LDHANPC1RAB9APPARGFFAR1 | |
| SCHEMBL24446771 | 0.84 | ANPEP (0.59) | LDHANPC1RAB9AATMALDH1A1 | |
| SCHEMBL9543477 | 0.84 | LDHA (0.51) | LDHANPC1RAB9APPARGFFAR1 | |
| SCHEMBL8948036 | 0.83 | ACE (0.49) | ACENPC1RAB9AFFAR1MEN1 | |
| SCHEMBL7614779 | 0.83 | ACE (0.49) | ACENPC1RAB9AFFAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023172648-A2 | FLUOROGENIC SUBSTRATES FOR AMINOPEPTIDASE DETECTION IN BIOFLUIDS | GLYMPSE BIO, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-1763509-B1 | ALPHA-HELICAL MIMETICS | WALTER & ELIZA HALL INST MEDICAL RES (AU) | 2018-02-21 | — | — | EP | disclosed |
| US-8039465-B2 | Cytoskeletal active compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039465-B2 | Cytoskeletal active compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-7956216-B2 | Benzoyl urea derivatives mimicing BH3-only proteins, able to interact with a Bcl-2 protein | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2011-06-07 | — | — | US | disclosed |
| US-7947850-B2 | Process for the preparation of 3,4-disubstituted-thiazolidin-2-ones | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947850-B2 | Process for the preparation of 3,4-disubstituted-thiazolidin-2-ones | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20100130572-A1 | CYTOSKELETAL ACTIVE COMPOUNDS, COMPOSITION AND USE | LAMPE JOHN W | 2010-05-27 | — | — | US | disclosed |
| US-20100130572-A1 | CYTOSKELETAL ACTIVE COMPOUNDS, COMPOSITION AND USE | LAMPE JOHN W | 2010-05-27 | — | — | US | disclosed |
| US-7666861-B2 | Cytoskeletal active compounds, composition and use | INSPIRE PHARMACEUTICALS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1763509-A1 | ALPHA-HELICAL MIMETICS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006104897-A2 | CYTOSKELETAL ACTIVE COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060217427-A1 | Cytoskeletal active compounds, compositions and use | INSPIRE PHARMACEUTICALS, INC. | 2006-09-28 | — | — | US | disclosed |
| WO-2006002474-A1 | ALPHA-HELICAL MIMETICS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2006-01-12 | — | — | WO | disclosed |
| EP-0444068-A1 | TRIALKYSILYL ESTERS OF AMINO ACIDS AND THEIR USE IN THE SYNTHESIS OF PEPTIDES | PUBLIC HEALTH LABORATORY SERVICE BOARD (GB) | 1991-09-04 | — | — | EP | disclosed |
| WO-1990005738-A1 | TRIALKYSILYL ESTERS OF AMINO ACIDS AND THEIR USE IN THE SYNTHESIS OF PEPTIDES | PUBLIC HEALTH LABORATORY SERVICE BOARD (GB) | 1990-05-31 | — | — | WO | disclosed |
| US-4497731-A | HORMONES | ARMOUR PHARMACEUTICAL COMPANY (US) | 1985-02-05 | — | — | US | disclosed |
| US-4412988-A | INFLUENCE OF MEMORY | ROUSSEL UCLAF (FR) | 1983-11-01 | — | — | US | disclosed |
| US-4239680-A | CALCITONIN ACITIVITY | ARMOUR AND COMPANY (US) | 1980-12-16 | — | — | US | disclosed |
| US-4113714-A | GROWTH HORMONE RELEASE INHIBITING UNDECAPEPTIDE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217427-A1 | Cytoskeletal active compounds, compositions and use | RHOA, ACTB, ROCK1 | LDHA 2736/4885ACE 1744/4885NPC1 2448/4885 |
| US-20100130572-A1 | CYTOSKELETAL ACTIVE COMPOUNDS, COMPOSITION AND USE | RHOA, ACTB, ROCK1 | LDHA 2817/4885ACE 1852/4885NPC1 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.